Latest Articles
Endometrial Cancer Market Expected to Witness Significant - openPR.com
Endometrial Cancer Market Expected to Witness Significant openPR.com
Published: Aug. 2, 2026, 5:51 p.m.
Living with endometriosis? Doctor explains why knowing the signs of ovarian cancer could make all the dif - The Times of India
Living with endometriosis? Doctor explains why knowing the signs of ovarian cancer could make all the dif The Times of India
Published: Aug. 2, 2026, 6:30 a.m.
Nicole ‘Snooki’ Polizzi reveals hysterectomy after cervical cancer diagnosis - NBC News
Nicole ‘Snooki’ Polizzi reveals hysterectomy after cervical cancer diagnosis NBC News
Published: Aug. 1, 2026, 4:30 p.m.
Karyopharm (KPTI) Shares Collapse 65% After Xpovio Fails Endometrial Cancer Trial Again - londoninsider.co.uk
Karyopharm (KPTI) Shares Collapse 65% After Xpovio Fails Endometrial Cancer Trial Again londoninsider.co.uk
Published: Aug. 1, 2026, 8:33 a.m.
Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial - The Clinical Trial Vanguard
Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial The Clinical Trial Vanguard
Published: Aug. 1, 2026, 6:33 a.m.
Karyopharm To Stick With Blood Cancers As Xpovio Flops In Endometrial Cancer - insights.citeline.com
Karyopharm To Stick With Blood Cancers As Xpovio Flops In Endometrial Cancer insights.citeline.com
Published: July 31, 2026, 8:31 p.m.
Selinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer - Targeted Oncology
Selinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer Targeted Oncology
Published: July 31, 2026, 8:06 p.m.
'The whole room froze': IVF scan leads to shock cancer diagnosis - NZ Herald
'The whole room froze': IVF scan leads to shock cancer diagnosis NZ Herald
Published: July 31, 2026, 6:04 p.m.
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - OncLive
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer OncLive
Published: July 31, 2026, 5:22 p.m.
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - onclive.com
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer onclive.com
Published: July 31, 2026, 5:22 p.m.
Link copied to clipboard!